Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: N/A
• Average Volume (3M): 3.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: 33.52%
• EPS Growth: 21.66%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 118,133,545
• 10 Day Avg. Volume: 5,229,060
• 30 Day Avg. Volume: 3,860,393
• PEG Ratio: 0.09
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 14.40
• P/FCF Ratio: -2.75
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 22.61
• Enterprise Value/Gross Profit: -88.49
• Enterprise Value/Ebitda: -3.66
• 1Y Price Target: $20.62
• Price Target Upside: 54.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): -3.65
• Revenue Forecast (FY): $58.74M

• Rating: 56 Neutral
• Price Target: $14.00 ▲(4.63% Upside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

Overall score reflects weak fundamentals typical of a development-stage biotech (persistent losses and cash burn) as the primary constraint. Offsetting this are improving technicals and a moderately positive clinical/regulatory outlook (upcoming pivotal lonvo-z catalysts and MAGNITUDE restart), while valuation support is limited given negative earnings and no dividend.

Positive Factors

Pivotal Lonvo‑z Progress

Completing Phase 3 enrollment and targeting a mid‑2026 readout crystallizes a near‑term regulatory path for a potential first‑in‑class in vivo CRISPR therapy. A successful readout and BLA would transition Intellia toward product revenues, validate platform scalability and materially de‑risk the lead commercial program.

Strong Market Demand

High patient and physician intent signals durable commercial uptake if approved. Early market research indicates a focused, addressable treated population and strong prescribing intent, supporting efficient launch planning, favorable uptake curves and sustainable one‑time therapy economics for gene‑editing modalities.

Financing Flexibility

A larger at‑the‑market program and meaningful prior sales provide optionality to extend runway without immediate large equity raises. This structural financing capacity, combined with existing cash, supports clinical continuity and commercial readiness efforts through key 2026–2027 milestones if deployed prudently.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow reflect structural funding needs to advance clinical programs. Continued cash burn erodes runway, forces reliance on external financing or partnerships, and can dilute shareholders or constrain investments in manufacturing and commercialization at critical launch stages.

Safety/Regulatory Uncertainty

A serious liver event and an ongoing clinical hold on a major ATTR‑CM program create durable regulatory risk for the in vivo platform. If the mechanism is immune‑mediated or not isolated, additional monitoring, label constraints, or broader holds could slow development, limit indications and raise commercialization complexity.

Revenue Volatility and Partner Dependence

Irregular, collaboration‑driven revenue undermines predictability and operating self‑sufficiency. Until product sales materialize, Intellia remains dependent on milestone payments and financings; this structural revenue instability increases execution risk around sustained R&D funding and commercial scale‑up.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Intellia Therapeutics generates revenue through a combination of research collaborations, licensing agreements, and potential future product sales. The company often partners with larger pharmaceutical firms, which provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, Intellia may receive royalties on the sales of any products developed through these collaborations. As the company advances its clinical programs and moves closer to commercialization, it may also begin to realize revenue from product sales once its therapies receive regulatory approvals. Key partnerships with organizations such as Regeneron Pharmaceuticals enhance its research capabilities and financial resources, contributing significantly to its earnings potential.

Intellia Therapeutics Financial Statement Overview

Summary

Financial profile remains pressured: sustained large net losses and consistently negative operating/free cash flow indicate ongoing cash burn. The balance sheet is a relative strength with modest leverage, but equity has been trending down due to persistent deficits.

Income Statement

Profitability remains a key weakness, with large net losses every year (2020–2025) and deeply negative profit margins in most periods. Revenue has been volatile: it grew in 2022 and 2024 but declined in 2021 and 2023, and fell to zero in 2025 (annual), reflecting high dependence on uneven collaboration/other revenue sources. A positive is that gross margin was strong in 2021–2024, indicating favorable unit economics when revenue is present, but operating costs continue to materially outweigh gross profit.

Balance Sheet

The balance sheet is a relative strength with low-to-moderate leverage, as debt-to-equity stayed modest (roughly 0.07–0.24) despite fluctuations in total debt. However, recurring net losses have driven consistently negative returns on equity and stockholders’ equity has trended down from 2022 to 2025, signaling ongoing capital consumption. Overall, solvency risk looks contained due to limited leverage, but the equity base is being pressured by persistent losses.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are consistently negative across all years, reflecting a business still funding operations through cash burn. Cash burn worsened in 2022–2023 versus 2021 and remained heavy in 2024–2025, with free cash flow declining again in 2025 (annual). A modest positive is that cash flow tracks net losses closely (free cash flow roughly in line with net income), suggesting losses are not being significantly exacerbated by non-cash working-capital swings—but the core issue remains the scale and persistence of cash burn.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	67.67M	57.88M	36.27M	52.12M	33.05M
Gross Profit	51.75M	47.59M	27.30M	44.55M	26.16M
EBITDA	-396.77M	-523.98M	-506.31M	-450.59M	-260.96M
Net Income	-412.69M	-519.02M	-481.19M	-474.19M	-267.89M
Balance Sheet
Total Assets	842.13M	1.19B	1.30B	1.52B	1.29B
Cash, Cash Equivalents and Short-Term Investments	449.88M	601.51M	912.22M	1.19B	748.69M
Total Debt	93.33M	210.20M	115.35M	130.70M	74.02M
Total Liabilities	170.73M	319.06M	250.81M	284.53M	254.22M
Stockholders Equity	671.39M	871.96M	1.05B	1.24B	1.04B
Cash Flow
Free Cash Flow	-354.66M	-354.66M	-408.07M	-391.68M	-237.79M
Operating Cash Flow	-348.88M	-348.88M	-394.09M	-333.29M	-225.03M
Investing Cash Flow	125.57M	125.57M	-31.35M	160.31M	-550.78M
Financing Cash Flow	185.75M	185.75M	130.32M	582.96M	736.69M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 13.38 is above the 20-day moving average (MA) of 13.37, above the 50-day MA of 12.70, and above the 200-day MA of 12.46, indicating a bullish trend. The MACD of 0.17 indicates Positive momentum. The RSI at 52.01 is Neutral, neither overbought nor oversold. The STOCH value of 23.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	56 Neutral	$1.58B	-2.54	-56.63%	―	33.52%	21.66%
BCAX	56 Neutral	$1.23B	-5.93	-27.17%	―	―	-103.95%
KURA	52 Neutral	$771.12M	-3.27	-102.59%	―	―	-5.18%
CMPX	52 Neutral	$974.28M	-12.74	-43.61%	―	-100.00%	-28.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	50 Neutral	$844.34M	-7.53	-11.55%	―	-23.37%	-42.45%
ABCL	49 Neutral	$1.08B	-6.98	-14.16%	―	7.16%	3.95%

Intellia Therapeutics Corporate Events

Intellia Resumes Key Trial and Expands ATM Program

On March 2, 2026, Intellia Therapeutics, Inc. amended its at-the-market equity offering agreement with Jefferies LLC, raising the total program size from $750 million to about $1.04 billion and filing a new prospectus supplement to cover up to $400 million in additional shares, including unsold capacity. As of that date, the company had already sold roughly $635.3 million of common stock under the program, reinforcing its financial flexibility while maintaining Jefferies as sales agent on a best-efforts basis with up to 3% compensation on gross proceeds.

Also on March 2, 2026, Intellia disclosed that the U.S. Food and Drug Administration lifted the clinical hold imposed on October 29, 2025, on its MAGNITUDE Phase 3 trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy and aligned on safety-focused mitigation measures for both MAGNITUDE and MAGNITUDE-2. The company is now working with investigators, ethics committees and international regulators to resume enrollment in these pivotal trials, a move that restores momentum to a key late-stage gene-editing program in a high-need cardiovascular and neurological indication.

The most recent analyst rating on (NTLA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial

On January 27, 2026, Intellia Therapeutics announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational new drug application for the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a hold that had been imposed on October 29, 2025 after a MAGNITUDE trial patient experienced severe liver toxicity and subsequently died. Following alignment with the FDA on protocol modifications and enhanced liver safety monitoring, Intellia plans to resume enrollment and dosing in MAGNITUDE-2, expand target enrollment from about 50 to 60 patients, and continue evaluating the efficacy and safety of a single 55 mg infusion of nex-z versus placebo; however, the separate MAGNITUDE Phase 3 trial in ATTR-CM remains on clinical hold as discussions with the agency continue, leaving a key part of the nex-z program and Intellia’s broader ATTR strategy still subject to regulatory uncertainty for patients, investigators and investors.

The most recent analyst rating on (NTLA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Updates Investors on Nex-Z Trial Safety Hold

On January 9, 2026, Intellia Therapeutics updated its corporate presentation to investors, detailing the status of its CRISPR-based pipeline and providing additional disclosure on a serious safety event tied to its lead ATTR amyloidosis candidate, nexiguran ziclumeran (nex-z). The company reiterated that a patient in the Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy experienced Grade 4 liver transaminase elevations and increased bilirubin, triggering a protocol-mandated trial pause and prompting the U.S. Food and Drug Administration to impose a clinical hold on both the MAGNITUDE and MAGNITUDE-2 Phase 3 studies; the patient subsequently died on November 5, 2025, with the principal investigator attributing the death to septic shock from a perforated duodenal ulcer amid a complex clinical course that included acute liver injury treated with corticosteroids. Intellia reported that more than 650 patients with ATTR-CM and 47 patients with hereditary ATTR amyloidosis with polyneuropathy have been enrolled across the two trials, with Grade 4 liver enzyme elevations observed in less than 1% of MAGNITUDE participants and none in MAGNITUDE-2, and said it will update stakeholders once it has agreed with regulators on a path forward for nex-z, underscoring both the regulatory risk around its flagship ATTR program and the broader safety and development uncertainties facing first-in-class in vivo CRISPR therapies.

The most recent analyst rating on (NTLA) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.